Clinical Trial Update: Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and efficacy of Everolimus (Afinitor) in Chinese adults with angiomyolipoma associated with tuberous sclerosis complex; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Angiomyolipoma
• Tuberous Sclerosis Complex

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Angiomyolipoma | Phase 4 | Status: COMPLETED | Results posted: 2021-09-09